The renoprotective effect of L-carnitine in hypertensive rats is mediated by modulation of oxidative stress-related gene expression

European Journal of Nutrition

Volumn 52, Issue 6, 2013, Pages 1649-1659

  Zambrano, Sonia ^a   Blanca, Antonio Jesús ^a   Ruiz Armenta, María Victoria ^a   Miguel Carrasco, José Luis ^a   Revilla, Elisa ^a   Santa María, Consuelo ^a   Mate, Alfonso ^a   Vázquez, Carmen María ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Hypertension; Kidney; L carnitine; L NAME; Nitric oxide; Oxidative stress; Renin angiotensin system

Indexed keywords

CARNITINE; DRINKING WATER; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N(G) NITROARGININE METHYL ESTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HYPERTENSION; KIDNEY CORTEX; KIDNEY FUNCTION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

ANIMALS; ANTIOXIDANTS; CARNITINE; DOWN-REGULATION; GENE EXPRESSION REGULATION; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HYPERTENSION; KIDNEY; LIPID PEROXIDATION; MALE; NADPH OXIDASE; NF-E2-RELATED FACTOR 2; NF-KAPPA B; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PPAR ALPHA; RATS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM; SUPEROXIDE DISMUTASE; SUPEROXIDES; UP-REGULATION;

EID: 84887606884     PISSN: 14366207     EISSN: 14366215     Source Type: Journal    
DOI: 10.1007/s00394-012-0470-x     Document Type: Article

References (52)

1. Touyz RM (2004) Reactive oxygen species and angiotensin II signaling in vascular cells-implications in cardiovascular disease. Braz J Med Biol Res 37:1263-1273
2. Manning RD Jr, Tian N, Meng S (2005) Oxidative stress and antioxidant treatment in hypertension and the associated renal damage. Am J Nephrol 25:311-317
3. Gomez-Amores L, Mate A, Miguel-Carrasco JL, Jimenez L, Jos A, Camean AM, Revilla E, Santa-Maria C, Vazquez CM (2007) L-Carnitine attenuates oxidative stress in hypertensive rats. J Nutr Biochem 18:533-540
4. Mate A, Miguel-Carrasco JL, Monserrat MT, Vazquez CM (2010) Systemic antioxidant properties of L-carnitine in two different models of arterial hypertension. J Physiol Biochem 66:127-136
5. Briones AM, Touyz RM (2010) Oxidative stress and hypertension: current concepts. Curr Hypertens Rep 12:135-142
6. Sedeek M, Hebert RL, Kennedy CR, Burns KD, Touyz RM (2009) Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Curr Opin Nephrol Hypertens 18:122-127
7. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubina P, Lahera V, Luno J (2008) Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int 74(Suppl 111):S4-S9
8. Rodriguez-Iturbe B, Zhan CD, Quiroz Y, Sindhu RK, Vaziri ND (2003) Antioxidant-rich diet relieves hypertension and reduces renal immune infiltration in spontaneously hypertensive rats. Hypertension 41:341-346
9. Garrido AM, Griendling KK (2009) NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol 302:148-158
10. Zicha J, Dobesova Z, Kunes J (2006) Antihypertensive mechanisms of chronic captopril or N-acetylcysteine treatment in L-NAME hypertensive rats. Hypertens Res 29:1021-1027
11. Cediel E, Sanz-Rosa D, Oubina MP, de las Heras N, Gonzalez Pacheco FR, Vegazo O, Jimenez J, Cachofeiro V, Lahera V (2003) Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function? Am J Physiol Regul Integr Comp Physiol 285:R674-R681
12. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, Kohno N, Yorioka N (2009) PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 89:47-58
13. Mate A, Miguel-Carrasco JL, Vazquez CM (2010) The therapeutic prospects of using L-carnitine to manage hypertension-related organ damage. Drug Discov Today 15:484-492
14. Arduini A, Bonomini M, Savica V, Amato A, Zammit V (2008) Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol Ther 120:149-156
15. Emami Naini A, Moradi M, Mortazavi M, Amini Harandi A, Hadizadeh M, Shirani F, Basir Ghafoori H, Emami Naini P (2012) Effects of oral L-carnitine supplementation on lipid profile, anemia, and quality of life in chronic renal disease patients under hemodialysis: a randomized, double-blinded, placebo-controlled trial. J Nutr Metab 2012(510483):1-6. doi:10.1155/2012/510483
16. Fatouros IG, Douroudos I, Panagoutsos S, Pasadakis P, Nikolaidis MG, Chatzinikolaou A, Sovatzidis A, Michailidis Y, Jamurtas AZ, Mandalidis D, Taxildaris K, Vargemezis V (2010) Effects of L-carnitine on oxidative stress responses in patients with renal disease. Med Sci Sports Exerc 42:1809-1818
17. Ruggenenti P, Cattaneo D, Loriga G, Ledda F, Motterlini N, Gherardi G, Orisio S, Remuzzi G (2009) Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl- L-carnitine therapy. Hypertension 54:567-574
18. Miguel-Carrasco JL, Monserrat MT, Mate A, Vazquez CM (2010) Comparative effects of captopril and L-carnitine on blood pressure and antioxidant enzyme gene expression in the heart of spontaneously hypertensive rats. Eur J Pharmacol 632:65-72
19. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
20. Gómez-Amores L, Mate A, Vázquez CM (2003) L-Carnitine transport in kidney of normotensive, Wistar-Kyoto rats: effect of chronic L-carnitine administration. Pharm Res 20:1133-1140
21. Marzinzig M, Nussler AK, Stadler J, Marzinzig E, Barthlen W, Nussler NC, Beger HG, Morris SM Jr, Bruckner UB (1997) Improved methods to measure end products of nitric oxide in biological fluids: nitrite, nitrate, and S-nitrosothiols. Nitric Oxide 1:177-189
22. Jentzsch AM, Bachmann H, Furst P, Biesalski HK (1996) Improved analysis of malondialdehyde in human body fluids. Free Radic Biol Med 20:251-256
23. Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70:158-169
24. Carlberg I, Mannervik B (1975) Purification and characterization of the flavoenzyme glutathione reductase from rat liver. J Biol Chem 250:5475-5480
25. Arthur JR, Boyne R (1985) Superoxide dismutase and glutathione peroxidase activities in neutrophils from selenium deficient and copper deficient cattle. Life Sci 36:1569-1575
26. Zalba G, Beaumont FJ, San Jose G, Fortuño A, Fortuño MA, Etayo JC, Diez J (2000) Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 35:1055-1061
27. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408
29. Chaves FJ, Mansego ML, Blesa S, Gonzalez-Albert V, Jimenez J, Tormos MC, Espinosa O, Giner V, Iradi A, Saez G, Redon J (2007) Inadequate cytoplasmic antioxidant enzymes response contributes to the oxidative stress in human hypertension. Am J Hypertens 20:62-69
30. Gomez-Amores L, Mate A, Revilla E, Santa-Maria C, Vazquez CM (2006) Antioxidant activity of propionyl-L-carnitine in liver and heart of spontaneously hypertensive rats. Life Sci 78:1945-1952
31. Duarte J, Jimenez R, O'Valle F, Galisteo M, Perez-Palencia R, Vargas F, Perez-Vizcaino F, Zarzuelo A, Tamargo J (2002) Protective effects of the flavonoid quercetin in chronic nitric oxide deficient rats. J Hypertens 20:1843-1854
32. Pedro-Botet J, Covas MI, Martin S, Rubies-Prat J (2000) Decreased endogenous antioxidant enzymatic status in essential hypertension. J Hum Hypertens 14:343-345
33. Saez GT, Tormos C, Giner V, Chaves J, Lozano JV, Iradi A, Redon J (2004) Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension. Am J Hypertens 17:809-816
34. Simic DV, Mimic-Oka J, Pljesa-Ercegovac M, Savic-Radojevic A, Opacic M, Matic D, Ivanovic B, Simic T (2006) Byproducts of oxidative protein damage and antioxidant enzyme activities in plasma of patients with different degrees of essential hypertension. J Hum Hypertens 20:149-155
35. Annadurai T, Vigneshwari S, Thirukumaran R, Thomas PA, Geraldine P (2011) Acetyl-L-carnitine prevents carbon tetrachloride- induced oxidative stress in various tissues of Wistar rats. J Physiol Biochem 67:519-530
36. Ye J, Li J, Yu Y, Wei Q, Deng W, Yu L (2010) L-Carnitine attenuates oxidant injury in HK-2 cells via ROS-mitochondria pathway. Regul Pept 161:58-66
37. Paravicini TM, Touyz RM (2008) NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 31(Suppl 2):S170-S180
38. Zalba G, San Jose G, Moreno MU, Fortuno MA, Fortuno A, Beaumont FJ, Diez J (2001) Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 38:1395-1399
39. Fortuño A, Olivan S, Beloqui O, San Jose G, Moreno MU, Diez J, Zalba G (2004) Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens 22:2169-2175
40. Moreno MU, San Jose G, Fortuño A, Beloqui O, Redon J, Chaves FJ, Corella D, Diez J, Zalba G (2007) A novel CYBA variant, the -675A/T polymorphism, is associated with essential hypertension. J Hypertens 25:1620-1626
41. Lassegue B, Clempus RE (2003) Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 285:R277-R297
42. Mister M, Noris M, Szymczuk J, Azzollini N, Aiello S, Abbate M, Trochimowicz L, Gagliardini E, Arduini A, Perico N, Remuzzi G (2002) Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. Kidney Int 61:1064-1078
43. Stasi MA, Scioli MG, Arcuri G, Mattera GG, Lombardo K, Marcellini M, Riccioni T, De Falco S, Pisano C, Spagnoli LG, Borsini F, Orlandi A (2010) Propionyl-L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPH-oxidase 4-mediated superoxide production. Arterioscler Thromb Vasc Biol 30:426-435
44. Surh YJ, Kundu JK, Na HK, Lee JS (2005) Redox-sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals. J Nutr 135:2993S-3001S
45. Calabrese V, Cornelius C, Mancuso C, Pennisi G, Calafato S, Bellia F, Bates TE, Giuffrida Stella AM, Schapira T, Dinkova Kostova AT, Rizzarelli E (2008) Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem Res 33:2444-2471
46. Pendyala S, Natarajan V (2010) Redox regulation of NOX proteins. Respir Physiol Neurobiol 174:265-271
47. Chen HH, Sue YM, Chen CH, Hsu YH, Hou CC, Cheng CY, Lin SL, Tsai WL, Chen TW, Chen TH (2009) Peroxisome proliferator- activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells. Nephrol Dial Transplant 24:3042-3049
48. Chao HH, Liu JC, Hong HJ, Lin JW, Chen CH, Cheng TH (2011) L-Carnitine reduces doxorubicin-induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes. Int J Cardiol 146:145-152
49. Jing L, Zhou LJ, Li WM, Zhang FM, Yuan L, Li S, Song J, Sang Y (2011) Carnitine regulates myocardial metabolism by Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha) in alcoholic cardiomyopathy. Med Sci Monit 17:BR1-BR9
50. San Jose G, Fortuño A, Moreno MU, Robador PA, Bidegain J, Varo N, Beloqui O, Diez J, Zalba G (2009) The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension. Clin Sci (Lond) 116: 233-240
51. Rajasekar P, Viswanathan P, Anuradha CV (2008) Renoprotective action of L-carnitine in fructose-induced metabolic syndrome. Diabetes Obes Metab 10:171-180
52. Miguel-Carrasco JL, Mate A, Monserrat MT, Arias JL, Aramburu O, Vazquez CM (2008) The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension. Am J Hypertens 21:1231-1237